The extent of duodenal bacterial overgrowth during the pronounced inhibition of acid secretion that occurs with omeprazole treatment is unknown. The 
weeks (mean (SEM)) treatment course with 20 mg (nine patients) or 40 mg (16 patients). The control group consisted of 15 outpatients referred for diagnostic endoscopy without prior antisecretory treatment. No patient in the control group had duodenal bacterial overgrowth. In the omeprazole group bacterial overgrowth (¢105 cfu/ml) was found in 14 (56%) patients (p=00003). The number of bacteria (log1o) in duodenal juice in patients treated with omeprazole was distinctly higher (median [5] [6] [7] ; range <28-87) when compared with the control group (median <2; range <2-5*0; p=00004). As well as orally derived bacteria, faecal type bacteria were found in seven of 14 and anaerobic bacteria in three of 14 patients. Bacterial overgrowth was similar with the two doses of omeprazole. These results indicate that duodenal bacterial overgrowth of both oral and faecal type bacteria occurs often in ambulatory patients treated with omeprazole. Further studies are needed to determine the clinical significance of these findings, particularly in high risk groups during long term treatment with omeprazole. (Gut 1994; 35: 23-26) Gastric acid plays an important part in the prevention of bacterial colonisation of the stomach and the small intestine.' Reduction of gastric acid secretion predisposes to infection with a variety of organisms. ' Figure 1 shows the type of bacteria (_ 104 cfu/ ml) identified in patients treated with omeprazole who had bacterial overgrowth. Haemolytic (12 patients) and non-haemolytic (10 patients) streptococci were mostly found. Gram negative Enterobacteriaceae, such as Klebsiella species (five patients), Escherischia coli (one patient) as well as Pseudomonas species (two patients), enterococci (one patient), and Bacteroides species (one patient) were identified in nine patients, and anaerobes in three patients (Bacteroides species in one patient and Clostridium species in two patients). In seven of 14 patients with bacterial overgrowth faecal type bacteria (Escherischia coli, Clostridium species, Bacteroides species, enterococci, and Klebsiella species) were found, whereas only oral and pharyngeal type bacteria were identified in the other seven patients.
Two patients treated with omeprazole who had bacterial overgrowth and one patient without overgrowth reported loose stools or diarrhoea.
Discussion
Gastric acid is a major defence factor against the bacterial colonisation ofthe small bowel and thus contributes to the prevention of bacterial overgrowth syndromes and intestinal infection.A89
In the past few years omeprazole -a drug with a high potency to inhibit gastric acid secretionhas been introduced into clinical practice. pH above 3 5-4 0 for proloni the pronounced inhibition of gastric acid secretion during omeprazole treatment may explain the development of duodenal bacterial overgrowth in most of our patients. The degree of bacterial colonisation was similar with 20 or 40 mg, which may be explained by the already profound inhibition of gastric acid secretion (>90%) by the lower dose.21 22 Conflicting results have been published about gastric bacterial overgrowth during treatment with other antisecretory drugs, in particular H2 antagonists. Several groups found an increased number of intragastric bacteria in patients receiving cimetidine'-5 17 24-27 or ranitidine, 18 23 although other groups were unable to confirm these findings.'2281 Omeprazole has been 8 10 12 reported to cause gastric bacterial overgrowth in healthy volunteers.'0 Few studies have investigated the incidence of duodenal bacterial al bacterial overgrowth overgrowth during treatment with H2 antago-'cies).
nists.?4-32 Two studies reported no bacterial overgrowth in the small intestine during treatment with cimetidine3' and ranitidine.3' The H2 breath lly cause bacterial tests used as the method of assessment has a low all intestine by its sensitivity and specificity, however." In one case tric acid secretion. report applying direct tube intubation of the k, no studies have jejunum, bacterial overgrowth was found to be a the bacterial flora cause of severe diarrhoea during cimetidine during treatment treatment.32
Most of the bacteria identified in our study by three considera-belong to species colonising the oral cavity and diminishes gastric pharynx, suggesting a descending route of antagonists5 and is colonisation. These results are in agreement with duodenal bacterial those of previous studies in patients treated with have previously H2 antagonists, where mostly bacteria originatazole raises intra-ing from the mouth were identified in gastric red periods, the pH contents.3 24-26 29 Similarly, omeprazole led to )urs in each day.'0 gastric colonisation with oral type bacteria in whether duodenal healthy volunteers.6 In half of our patients with during omeprazole bacterial overgrowth, however, faecal type by theoretical con-bacteria were also found including anaerobes. he methods used so Thus it seems that omeprazole may also cause cterial overgrowth ascending colonisation of the upper small nt with H2 antag-intestine. sts) and lack sensiWhat are the clinical consequences of duoly direct intubation denal bacterial overgrowth during omeprazole 'ovide reliable data treatment, as shown in this investigation? The small intestine.34" design of the study and the small number of rst investigation to patients do not allow us to draw firm conclusions acterial overgrowth about the frequency of symptoms attributable to -nt. Also, it is the small intestinal bacterial overgrowth. Patients acterial flora of the were treated with omeprazole for short periods, .ated with omepra-and few reported side effects; however, the c intubation of the development of clinically significant manifestarial overgrowth in tions of bacterial overgrowth syndromes treated with 20-40 depends on the presence of anaerobic bacteria in Lr to eight weeks, a the upper small intestine over prolonged applied in everyday periods.34 Anaerobic colonisation can be associated with the development of vitamin B12 ie stomach and the deficiency and malabsorption syndromes with Is on the degree of steatorrhea,34 and recently, omeprazole has been id secretion.'891 [12] [13] [14] [15] [16] [17] [18] [19] 
